# Study to Evaluate the ECG Effects of Telaglenastat in Healthy Adult Subjects

> **NCT04607512** · PHASE1 · COMPLETED · sponsor: **Calithera Biosciences, Inc** · enrollment: 30 (actual)

## Conditions studied

- Cardiac Safety

## Interventions

- **DRUG:** telaglenastat
- **OTHER:** telaglenastat placebo
- **OTHER:** moxifloxicin

## Key facts

- **NCT ID:** NCT04607512
- **Lead sponsor:** Calithera Biosciences, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-05
- **Primary completion:** 2020-12-30
- **Final completion:** 2020-12-30
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2021-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04607512

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04607512, "Study to Evaluate the ECG Effects of Telaglenastat in Healthy Adult Subjects". Retrieved via AI Analytics 2026-09-24 from https://api.ai-analytics.org/clinical/NCT04607512. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*